EPP sales (1 and only specific approval for scenesse -no off label option available -and locked down to costly special centres) have plateaued, even though <10% of sufferers have gained access (over 5-10 years) to the ONLY drug that works for their debilitating disease -so effective it’s literally life changing!it is certainly hard to understand how the EPP rollout could be so poorly managed. 95% long term adherence, no significant side effects but less than 10 % market penetration. Wolgen and hay tell us this is better than they expected. An embarrassing disgrace.
Ann: CLINUVEL Newsletter II - March 2024, page-20
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.39 |
Change
0.430(2.87%) |
Mkt cap ! $771.0M | |||
| Open | High | Low | Value | Volume |
| $14.96 | $15.39 | $14.83 | $2.149M | 141.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 590 | $15.29 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.41 | 1079 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| CUV (ASX) Chart |